FindTrial
Sign In

A study to understand the effect of Ticagrelor, an oral antiplatelet medication that helps prevent blood clots in Indian patients with Acute Coronary Syndrome

A Real-World Retrospective Study to evaluate Effectiveness and Tolerability of Ticagrelor in Indian patients with Acute Coronary SyndRome (STAR Study)

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/06/089010
Enrollment
5000
Registered
2025-06-17
Start date
Unknown
Completion date
Unknown
Last updated
2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I20-I25- Ischemic heart diseases

Interventions

Intervention1: Nil: Nil Control Intervention1: Nil: Nil

Sponsors

Sun Pharma Laboratories Limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Male or female patients of age greater than or equal to 18 years Patients prescribed ticagrelor for any of the specified indications [(Ticagrelor is indicated for the prevention of thrombotic events in patients with Acute coronary syndrome (ACS), unstable angina, non-ST elevation myocardial infarction (NSTEMI), or ST elevation myocardial infarction (STEMI) including the patients managed medically and those who are managed with percutaneous intervention (PCI) or coronary artery bypass grafting (CABG)] Patients with EMR data captured for more than one visit

Exclusion criteria

Exclusion criteria: Pregnant females and nursing mothers Patients prescribed ticagrelor for conditions other than ones specified [Ticagrelor is indicated for the prevention of thrombotic events in patients with Acute coronary syndrome (ACS), unstable angina, non-ST elevation myocardial infarction (NSTEMI), or ST elevation myocardial infarction (STEMI) including the patients managed medically and those who are managed with percutaneous intervention (PCI) or coronary artery bypass grafting (CABG)] Patients with incomplete medical records with respect to the required study parameters

Design outcomes

Primary

MeasureTime frame
Proportion of patients with cardiovascular events during the study periodTimepoint: Baseline to end of study—

Secondary

MeasureTime frame
Drug utilization pattern of ticagrelor and other antiplatelet agents during the study periodTimepoint: Baseline to end of study;Incidence and type of cardiovascular events during the study periodTimepoint: Baseline to end of study;Proportion of patients with adverse events during the study periodTimepoint: Baseline to end of study—

Countries

India

Contacts

Public ContactMs Colette Pinto

Sun Pharma Laboratories Limited

Neeraj.Markandeywar@sunpharma.com9022797378

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026